Femasys (FEMY) to Announce Earnings on Wednesday

Femasys (NASDAQ:FEMY) is expected to be posting its Q2 2026 results before the market opens on Wednesday, August 12th. Analysts expect Femasys to announce earnings of ($1.2667) per share and revenue of $0.7310 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Femasys (NASDAQ:FEMY) last announced its quarterly earnings results on Friday, May 8th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($1.33) by $1.43. The firm had revenue of $0.42 million for the quarter, compared to analyst estimates of $0.77 million. Femasys had a negative return on equity of 258.08% and a negative net margin of 521.97%.

Femasys Stock Performance

NASDAQ:FEMY opened at $3.05 on Wednesday. The stock’s 50-day moving average is $4.36 and its 200-day moving average is $7.86. Femasys has a 1-year low of $2.64 and a 1-year high of $22.20. The company has a current ratio of 3.91, a quick ratio of 1.98 and a debt-to-equity ratio of 0.53. The stock has a market cap of $9.21 million, a P/E ratio of -0.56 and a beta of -2.08.

Hedge Funds Weigh In On Femasys

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC bought a new stake in Femasys in the second quarter valued at approximately $82,000. Osaic Holdings Inc. acquired a new stake in Femasys during the 2nd quarter valued at approximately $45,000. Geode Capital Management LLC raised its holdings in Femasys by 50.8% during the 4th quarter. Geode Capital Management LLC now owns 389,280 shares of the company’s stock worth $224,000 after purchasing an additional 131,052 shares during the last quarter. Kovack Advisors Inc. bought a new position in Femasys during the 4th quarter worth approximately $27,000. Finally, Banco BTG Pactual S.A. acquired a new position in shares of Femasys in the 4th quarter worth approximately $88,000. 65.27% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Wall Street Zen raised shares of Femasys to a “hold” rating in a report on Saturday, June 13th. Weiss Ratings raised shares of Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $106.67.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.